Evidence map›Paper›PMID 28533682›Full record

ArticleInternational journal of nanomedicine2017

Polyethylene glycol-poly(ε-benzyloxycarbonyl-l-lysine)-conjugated VEGF siRNA for antiangiogenic gene therapy in hepatocellular carcinoma.

Gangmin Wang, XiaoLong Gao, GuoJun Gu, ZhiHong Shao, MingHua Li, PeiJun Wang, JianRong Yang, XiaoJun Cai, YongYong Li

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of nanomedicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Gangmin WangDepartment of Urology, Huashan Hospital, Fudan University.
XiaoLong GaoDepartment of Radiology, Tongji Hospital, School of Medicine, Tongji University, Shanghai.
GuoJun GuDepartment of Radiology, Tongji Hospital, School of Medicine, Tongji University, Shanghai.
ZhiHong ShaoDepartment of Radiology, Tongji Hospital, School of Medicine, Tongji University, Shanghai.
MingHua LiDepartment of Radiology, Tongji Hospital, School of Medicine, Tongji University, Shanghai.
PeiJun WangDepartment of Radiology, Tongji Hospital, School of Medicine, Tongji University, Shanghai.
JianRong YangDepartment of Hepatobiliary Surgery, Third People's Hospital of Guangxi Zhuang Autonomous Region, Nanning.
XiaoJun CaiInstitute for Advanced Materials and Nano Biomedicine, School of Material Science and Engineering, Tongji University, Shanghai, People's Republic of China.
YongYong LiInstitute for Advanced Materials and Nano Biomedicine, School of Material Science and Engineering, Tongji University, Shanghai, People's Republic of China.
Tongji University · CNRiverside Hospital of Guangxi Zhuang Autonomous Region · CNTongji Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A polyethylene glycol-poly(ε-benzyloxycarbonyl-l-lysine) (PEG-SS-PLL) block copolymer based on a disulfide-linked, novel biodegradable catiomer bearing a PEG-sheddable shell was developed to avoid "PEG dilemma" in nanoparticle intracellular tracking of PEG-PLL where PEG was nondegradable. However, PEG-SS-PLL catiomers have not been used to deliver small interfering VEGF RNA (siVEGF) in antiangiogenesis gene therapy. In this study, we aimed to investigate whether this novel biodegradable catiomer can deliver siVEGF into cancer cells and at the same time have an antitumor effect in a xenograft mouse model. It was found that PEG-SS-PLL efficiently delivered siVEGF with negligible cytotoxicity, and significantly decreased the expression of VEGF at both the messenger-RNA and protein levels both in vitro and in vivo, and thus tumor growth was inhibited. Our findings demonstrated that PEG-SS-PLL/siVEGF could potentially be applied to antiangiogenesis gene therapy for hepatocellular carcinoma.

Indexed as

Angiogenesis InhibitorsAnimalsCarcinoma, HepatocellularDrug Delivery SystemsFemaleGenetic TherapyHep G2 CellsHumansLiver NeoplasmsLysineMice, Inbred BALB CNanoparticlesPolyethylene GlycolsPolylysinePolymersRNA, Small InterferingAngiogenesis InhibitorsLysinepolyethylene glycol bis(succinimidyl succinate)polyethylene glycol-poly(epsilon-benzyloxycarbonyllysine)Polyethylene GlycolsPolylysinePolymersRNA, Small InterferingSuccinimidesVascular Endothelial Growth Factor Aantiangiogenesisdisulfidehepatocellular carcinomapolyethylene glycolpoly lysinesiRNAVEGF

Identifiers

PMID28533682
PMCPMC5431695
OpenAlexW2612340422

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.